From: PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours
Cmax (mg/L)
AUC (mg/L*hr)
t1/2(hr)
Gemcitabine
20.8 ± 10.6
4.87 ± 1.69
0.21 ± 0.06
Difluorodeoxyuridine
30.8 ± 9.56
219 ± 57.6
12.2 ± 2.34